In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
After finishing at $1.44 in the prior trading day, Standard BioTools Inc (NASDAQ: LAB) closed at $1.43, down -0.69%. In other words, the price has decreased by -$0.69 from its previous closing price. On the day, 1.02 million shares were traded. LAB stock price reached its highest trading level at $1.5099 during the session, while it also had its lowest trading level at $1.425.
Ratios:
Our goal is to gain a better understanding of LAB by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.14 and its Current Ratio is at 4.38. In the meantime, Its Debt-to-Equity ratio is 0.07 whereas as Long-Term Debt/Eq ratio is at 0.06.
On April 16, 2024, TD Cowen started tracking the stock assigning a Buy rating and target price of $3.50.TD Cowen initiated its Buy rating on April 16, 2024, with a $3.50 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Dec 04 ’25 when Casdin Partners Master Fund, L bought 150,000 shares for $1.45 per share. The transaction valued at 217,020 led to the insider holds 72,100,000 shares of the business.
Casdin Partners Master Fund, L bought 125,000 shares of LAB for $177,512 on Dec 02 ’25. The Director now owns 71,875,000 shares after completing the transaction at $1.42 per share. On Dec 03 ’25, another insider, Casdin Partners Master Fund, L, who serves as the Director of the company, bought 75,000 shares for $1.44 each. As a result, the insider paid 108,037 and bolstered with 71,950,000 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, LAB now has a Market Capitalization of 549928512 and an Enterprise Value of 192809360. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.27 while its Price-to-Book (P/B) ratio in mrq is 1.37. Its current Enterprise Value per Revenue stands at 1.136 whereas that against EBITDA is -1.556.
Stock Price History:
The Beta on a monthly basis for LAB is 1.25, which has changed by -0.25906736 over the last 52 weeks, in comparison to a change of 0.13506866 over the same period for the S&P500. Over the past 52 weeks, LAB has reached a high of $2.25, while it has fallen to a 52-week low of $0.92. The 50-Day Moving Average of the stock is 10.22%, while the 200-Day Moving Average is calculated to be 16.91%.
Shares Statistics:
The stock has traded on average 1.65M shares per day over the past 3-months and 2539960 shares per day over the last 10 days, according to various share statistics. A total of 383.61M shares are outstanding, with a floating share count of 368.50M. Insiders hold about 4.18% of the company’s shares, while institutions hold 75.45% stake in the company. Shares short for LAB as of 1763078400 were 11856210 with a Short Ratio of 7.17, compared to 1760486400 on 11839646. Therefore, it implies a Short% of Shares Outstanding of 11856210 and a Short% of Float of 4.82.
Earnings Estimates
At present, 2.0 analysts are actively evaluating the performance of Standard BioTools Inc (LAB) in the stock market.The consensus estimate for the next quarter is -$0.01, with high estimates of -$0.01 and low estimates of -$0.02.
Analysts are recommending an EPS of between -$0.1 and -$0.12 for the fiscal current year, implying an average EPS of -$0.11. EPS for the following year is -$0.04, with 1.0 analysts recommending between -$0.04 and -$0.04.
Revenue Estimates
3 analysts predict $18.5M in revenue for. The current quarter. It ranges from a high estimate of $19.3M to a low estimate of $17.8M. As of. The current estimate, Standard BioTools Inc’s year-ago sales were $46.72MFor the next quarter, 3 analysts are estimating revenue of $18.6M. There is a high estimate of $20.7M for the next quarter, whereas the lowest estimate is $16.4M.
A total of 3 analysts have provided revenue estimates for LAB’s current fiscal year. The highest revenue estimate was $80.8M, while the lowest revenue estimate was $79.9M, resulting in an average revenue estimate of $80.27M. In the same quarter a year ago, actual revenue was $174.43MBased on 3 analysts’ estimates, the company’s revenue will be $79.73M in the next fiscal year. The high estimate is $81.5M and the low estimate is $77.4M.
